Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.57 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL28129614 | 0.93 | TSHR (0.56) | TSHRSLC22A1SLC22A2ALDH1A1TP53 | |
| SCHEMBL2935402 | 0.93 | TSHR (0.62) | TSHRSLC22A1SLC22A2ALDH1A1TP53 | |
| Hydrogen Sulfide SCHEMBL28156175 | 0.87 | — | — | |
| SCHEMBL3402684 | 0.86 | SLC22A1 (0.62) | TSHRSLC22A1SLC22A2ALDH1A1TP53 | |
| SCHEMBL3395180 | 0.86 | SLC22A1 (0.62) | TSHRSLC22A1SLC22A2ALDH1A1TP53 | |
| Water SCHEMBL27972168 | 0.84 | — | — | |
| SCHEMBL21555 | 0.84 | — | — | |
| SCHEMBL27494430 | 0.84 | TSHR (0.81) | TSHRSLC22A1SLC22A2ALDH1A1CYP3A4 | |
| SCHEMBL11095447 | 0.82 | TSHR (0.77) | TSHRALDH1A1HSD17B10DNM1 | |
| Hydrochloric Acid SCHEMBL9369710 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016250-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2017281-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | ISHIBASHI MICHIO (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6878745-B2 | Selective preventives/remedies for progressive lesions after organ damage | Ishibashi, Michio (JP) | 2005-04-12 | — | — | US | disclosed |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | ISHIBASHI, MICHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1277747-A1 | SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE | Ishibashi, Michio (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016250-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | TLR9, TLR1, TLR7 | TSHR 1845/4885SLC22A1 1916/4885SLC22A2 2333/4885 |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | CCL11, CD68, CCL2 | TSHR 3380/4885SLC22A1 925/4885SLC22A2 1148/4885 |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | CD68, MSR1, CCL2 | TSHR 3555/4885SLC22A1 1340/4885SLC22A2 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.